
|Videos|July 27, 2015
Mechanisms of Action for New Weight-Loss Agents
Advertisement
Episodes in this series

Jennifer L. Costello, PharmD, BCPS, BC-ADM, ambulatory care clinical pharmacist at Saint Barnabas Medical Center, reviews the pharmacologic mechanisms in the new weight-loss drugs.
Liraglutide, a glucagon-like peptide-1 receptor agonist, helps improve insulin secretion and reduce glucagon release. The drug dramatically affects patient satiation, so they eat less, Dr. Costello notes. It also causes some gastrointestinal upset, which can make some patients eat less.
Meanwhile, the naltrexone/bupropion combination affects central nervous system synapses by augmenting or modulating the craving zone—causing patients to have fewer food cravings.
Advertisement
Related to this article

BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.

A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.

Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.

American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.

fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.

Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.

A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
Advertisement
Advertisement








